Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Essen Biotech
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07410676CT.gov EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05700461CT.gov Drug Screening Using Novel IMD in Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT06364631CT.gov CARE1 Pragmatic Clinical Trial | — | Recruiting | — | — | — |
NCT05969496CT.gov Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus | — | Recruiting | — | — | — |
NCT05708950CT.gov A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | — | Completed | — | — | — |
NCT05070247CT.gov A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT04393350CT.gov Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03736330CT.gov A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma | — | Unknown | — | — | — |
NCT03280667CT.gov Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma | — | Unknown | — | — | — |
NCT03189186CT.gov Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas | — | Withdrawn | — | — | — |
Show 2 more trialsShow fewer
NCT02964078CT.gov Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT00126178CT.gov Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Essen Biotech | Approved | BB · 65 |
| Alpha-Interferon | Dartmouth-Hitchcock Medical Center | P3 | BBB |
| Girentuximab | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BB |
| Etoposide | City of Hope Medical Center | P3 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Fluorouracilum | Medical Research Council | P3 | BB |
| Lenvatinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Sargramostim | Barbara Ann Karmanos Cancer Institute | P2 | BB |
+42 more in the Kidney Cancer cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Kidney Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-kidney-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →